What adverse effect is commonly associated with Eptifibatide?

What adverse effect is commonly associated with Eptifibatide?

• A. Hypertension
• B. Bleeding
• C. Nervousness
• D. Dizziness

Answer: (B)

Eptifibatide is an antiplatelet agent that works by inhibiting the glycoprotein IIb/IIIa receptor on platelets, which is crucial for platelet aggregation and thrombus formation. One of the most significant adverse effects associated with its use is bleeding. This occurs because by inhibiting platelet aggregation, Eptifibatide effectively reduces the blood's ability to clot. As a result, patients receiving Eptifibatide may be at an increased risk for bleeding complications, which can manifest as easy bruising, nosebleeds, or more serious internal bleeding. The other options presented—hypertension, nervousness, and dizziness—are not typically associated with Eptifibatide. While dizziness may occur in some instances, it is generally less common and not the primary concern compared to the risk of bleeding. Understanding this association is critical for healthcare providers when monitoring patients on Eptifibatide and managing their overall treatment strategy.

Eptifibatide is an antiplatelet agent that works by inhibiting the glycoprotein IIb/IIIa receptor on platelets, which is crucial for platelet aggregation and thrombus formation. One of the most significant adverse effects associated with its use is bleeding. This occurs because by inhibiting platelet aggregation, Eptifibatide effectively reduces the blood's ability to clot. As a result, patients receiving Eptifibatide may be at an increased risk for bleeding complications, which can manifest as easy bruising, nosebleeds, or more serious internal bleeding.

The other options presented—hypertension, nervousness, and dizziness—are not typically associated with Eptifibatide. While dizziness may occur in some instances, it is generally less common and not the primary concern compared to the risk of bleeding. Understanding this association is critical for healthcare providers when monitoring patients on Eptifibatide and managing their overall treatment strategy.